Delivery Order SPE2DB25D3109-SPE2DB26FP4QF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL formulation, valued at $6,797.70 with a firm fixed price structure. Awarded on September 15, 2025, this non-set-aside delivery order is scheduled for completion by September 16, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL pre-filled pens, with a contract ceiling value of $2,265.90. This is a firm fixed-price, competitively awarded delivery order issued without a set-aside designation, with an ultimate completion date of August 13, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- The Defense Logistics Agency awarded a $6,596.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL concentration. This is a non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen...
- The Defense Logistics Agency awarded a $4,852.12 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,021.20 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL. This is a firm fixed-price contract with no set-aside designation, executed on June 3, 2025, with an ultimate completion date of June 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order valued at $13,438.22 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside contract with a completion date of May 13, 2025, one day after the award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB26FP4QFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens (40 mg/0.4 mL) valued at $2,265.90 with a firm fixed price contract type. This award, issued November 5, 2025, is a non-set-aside competitive procurement executed as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle supporting pharmaceutical procurement through December 2026. The product will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with completion expected by November 6, 2025. This delivery order represents a routine pharmaceutical procurement supporting the Defense Health Agency and broader military healthcare systems. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, regularly fulfills critical medical supply needs for federal defense and veteran healthcare programs through its comprehensive IDC vehicle. The company's federal contract portfolio demonstrates extensive capability in delivering both brand-name specialty medications and generic pharmaceuticals across multiple therapeutic domains, positioning it as a key vendor within the DLA's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 11/5/25 |